Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00102778 · ClinicalTrials.gov registry record · Phase 2

GW873140 In Combination With Kaletra In HIV Infected Subjects

A Phase 2 study, sponsored by ViiV Healthcare.

Terminated
Registry status
Phase 2
Development phase
175
Enrollment target

NCT00102778: Clinical Trial Phase 2 study, sponsored by ViiV Healthcare.

NCT00102778 is a Phase 2 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 175 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00102778, a Phase 2 study, was terminated before completion, sponsored by ViiV Healthcare.

TERMINATED
Registry status
Phase 2
Development phase
175 participants
Enrollment target

Study Summary

This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.

Interventions

  • DRUG Kaletra (lopinavir/ritonavir)
  • DRUG GW873140

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2004-12
Est. Completion 2007-09
Phase Phase 2
ViiV Healthcare

182 total trials

Why NCT00102778 stopped before completion

NCT00102778 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).

The record links to 0 conditions, and to 2 interventions - of which Kaletra (lopinavir/ritonavir) is the first listed.

NCT00102778 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00102778 about?

NCT00102778 is a clinical study titled "GW873140 In Combination With Kaletra In HIV Infected Subjects". This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.

What is the current status of trial NCT00102778?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2004-12. Estimated completion is 2007-09.

What interventions are being tested in trial NCT00102778?

The interventions under investigation include: Kaletra (lopinavir/ritonavir) (DRUG), GW873140 (DRUG).

Who is sponsoring clinical trial NCT00102778?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00102778's enrollment target sits among peer trials

175 396th of 2000 higher than 1,605 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05165745 · 175 participants · NA

    Stick2PrEP Cisgender Women and Trans Individuals

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00102778, the US trial registry maintained by the National Library of Medicine. NCT00102778 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.